All In Biotech

Drug Trial Radar · NCT04078295

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

125

Actual

Start

Sep 5, 2019

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Sep 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate safety and tolerability of E7389 liposomal formulation (E7389-LF) in combination with nivolumab and to determine the recommended Phase 2 dose (RP2D) in Phase 1b part and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in each tumor type in Phase 2 part.

Conditions

  • Solid Neoplasms

Interventions

  • E7389-LFDrug

    E7389-LF Intravenous infusion.

  • NivolumabDrug

    Nivolumab Intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Baseline up to Cycle 1 (Cycle length is equal to [=] up to 28 days)
  2. Phase 2: ORRTime frame: Baseline up to End of Treatment (Up to approximately 79 months)

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai Trial Site #12

    Kōtoku, Japan

  • Eisai Trial Site #13

    Nagoya, Aichi-ken, Japan

  • Eisai Trial Site #18

    Kashiwa, Chiba, Japan

  • Eisai Trial Site #2

    Kashiwa, Chiba, Japan

  • Eisai Trial Site #14

    Matsuya, Ehime, Japan

  • Eisai Trial Site #4

    Kurume, Fukuoka, Japan

  • Eisai Trial Site #11

    Akashi, Hyōgo, Japan

  • Eisai Trial Site #15

    Yokohama, Kanaga, Japan

  • Eisai Trial Site #3

    Sendai, Miyagi, Japan

  • Eisai Trial Site #6

    Chuo Ku, Osaka, Japan

  • Eisai Trial Site #8

    Chuo Ku, Osaka, Japan

  • Eisai Trial Site #5

    Osakasa, Osaka, Japan

  • Eisai Trial Site #7

    Sakai C, Osaka, Japan

  • Eisai Trial Site #17

    Suita, Osaka, Japan

  • Eisai Trial Site #19

    Kitaadachi-gun, Saitama, Japan

  • Eisai Trail Site #16

    Sunto-g, Shizuo, Japan

  • Eisai Trial Site #1

    Chuo Ku, Tokyo, Japan

  • Eisai Trial Site #10

    Koto-Ku, Tokyo, Japan

  • Eisai Trial Site #9

    Wakayama, Wakaya, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.